Covidien launches 2 trials to support its Stellarex drug-device combo

July 17, 2013 by Sony Salzman

Covidien begins enrollment in a pair of clinical studies evaluating its Stellarex drug-coated angioplasty balloon in the U.S. and abroad.

Covidien launched 2 trials to support its Stellarex drug-device combo

Covidien (NYSE:COV) kicked off 2 new clinical trials this week to support a global evaluation of its Stellarex drug-coated angioplasty balloon.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp